Fischer Medical Ventures Limited announced its unaudited Q1 FY26 results on 14 August 2025.

• Financial Highlights (Q1 FY26 vs Q1 FY25):

  • Standalone: Revenue at Rs. 454.23 lakhs; net loss of Rs. 60.94 lakhs (vs. net profit Rs. 83.94 lakhs). Operating margin: -4.75%; net margin: -13.42%.
  • Consolidated: Revenue at Rs. 2,344.47 lakhs (more than doubled YoY); net profit Rs. 500.82 lakhs (vs. net loss Rs. 11.71 lakhs). Operating margin: 43.4%; net margin: 21.36%.
  • Standalone finance costs increased significantly to Rs. 130.88 lakhs, impacting profitability. Consolidated employee expenses rose sharply.

• Auditor’s Report: Clean limited review with unmodified opinion; no qualifications or concerns.

• Corporate Actions: Resignation of Independent Director Dr. Jacob Thomas effective 14 August 2025; appointment of M/s Nuren Lodaya & Associates as AGM Scrutinizer.

• Segment & Geography: No segment-wise financials disclosed; consolidated results include multiple subsidiaries and associates across India and Southeast Asia.

• Capex/Projects: No disclosures on capital expenditure, projects, acquisitions, or restructuring.

• Accounting Policies: No changes or material adjustments reported.

• Outlook: No management commentary or guidance provided in the filing.

This summary reflects key financial and corporate developments as per the Q1 FY26 filing.